Last updated: July 8, 2026
Allergan Sales LLC v. Aurobindo Pharma USA Inc. (1:18-cv-00118) — Litigation Summary, Patent Claims, and Commercial Impact
Executive summary: Allergan Sales LLC sued Aurobindo Pharma USA Inc. in 1:18-cv-00118 asserting patent infringement tied to an FDA-abbreviated approval and the associated Orange Book-listed patents. The case is procedurally aligned with a Hatch-Waxman Paragraph IV framework, and its outcome determines the timing window for Aurobindo’s generic launch for the asserted product and patent estate.
What this matters commercially: The suit’s asserted patents, their remaining term, and the court’s disposition drive (1) entry timing, (2) settlement or licensing likelihood, and (3) at-risk exposure for Allergan’s branded revenue versus Aurobindo’s generic sales trajectory.
What happened in Allergan Sales LLC v. Aurobindo Pharma USA Inc. (1:18-cv-00118)?
Core posture (Hatch-Waxman / Paragraph IV pattern):
This matter tracks the standard Hatch-Waxman infringement workflow where a brand manufacturer alleges that an ANDA applicant’s submitted notice of certification (typically Paragraph IV) infringes specific Orange Book patents listed for the reference listed drug (RLD).
Case identifier:
- Court docket: 1:18-cv-00118
- Parties: Allergan Sales LLC (plaintiff) vs Aurobindo Pharma USA Inc. (defendant)
Patent-and-ANDA linkage (what the litigation is about):
In these suits, the complaint and infringement content typically specify:
- which Orange Book-listed patents are asserted,
- which ANDA product practices the claims, and
- which claims are infringed via the ANDA-manufactured formulation, dosage form, and/or method-of-use.
Because this is an infringement action under 35 U.S.C. § 271(e)(2), the litigation turns on whether the ANDA product infringes the asserted claims and whether the asserted claims are invalid or unenforceable.
Which patents did Allergan assert against Aurobindo in 1:18-cv-00118?
Answer in litigation terms: The lawsuit’s asserted-patent set is the driver of both legal strategy and exclusivity/launch risk. In an ANDA infringement case, brand plaintiffs typically assert:
- composition/formulation patents covering active ingredient and/or specific drug substance + excipient combinations,
- method-of-use patents covering dosing or therapeutic regimens, and/or
- pharmacokinetic / formulation performance patents linked to the ANDA’s claimed regimen.
Operational note for risk modeling:
For exclusivity and entry timing, the key is whether any asserted patent is:
- a primary patent with enforceable claims close to expiration, or
- a secondary patent that might be carved out by claim construction or invalidity rulings.
Litigation mapping needed for a complete analysis:
A complete patent-claim-by-claim summary requires the complaint’s asserted patent numbers and the court’s dispositive filings (e.g., claim construction, summary judgment, infringement findings). This information is not contained in the prompt provided here, so a fully accurate identification of the patents and claim scope cannot be produced.
What is the procedural timeline for 1:18-cv-00118 (filing, motions, rulings)?
Typical sequence in ANDA Paragraph IV cases (framework):
- Complaint filed by the brand within the statutory window after receipt of the Paragraph IV notice.
- Answer and establishment of scheduling order.
- Markman/claim construction or stipulations affecting claim interpretation.
- Infringement and validity briefing for dispositive motions (often summary judgment).
- Trial or settlement (with timing tied to patent expiration, injunction risk, and remaining term).
- Dismissal or consent judgment if settlement resolves entry and/or design-arounds.
What governs timing leverage:
- If the court construes key claims narrowly, generic entry risk can increase or decrease depending on how the ANDA is designed.
- If the court finds invalidity of a primary asserted patent, the remaining asserted patents become the only barrier.
- If the parties settle, the terms (entry date, carve-outs, royalties, covenant-not-to-sue scope) become the immediate commercial determinant.
Limitation:
Without the docket entries (e.g., complaint filing date, claim construction dates, summary judgment orders, settlement docket events), a case-specific timeline cannot be stated accurately.
Did Allergan win, settle, or lose in 1:18-cv-00118?
Commercially decisive question:
Outcome determines whether Aurobindo’s ANDA launch was:
- enjoined (high barrier remained),
- delayed until patent expiry or later adjudicated dates,
- permitted on a design-around or invalidation theory, or
- governed by a settlement agreement with defined launch timing and permitted commercial conduct.
Limitation:
A precise litigation conclusion (judgment outcome, dismissal basis, or settlement terms) cannot be produced from the prompt alone.
What does this litigation mean for generic entry risk of Aurobindo’s ANDA?
Generic entry risk drivers in Hatch-Waxman:
- Remaining term of asserted patents at the time of judgment/settlement.
- Whether the asserted claims are upheld for infringement.
- Whether the court rejects invalidity defenses.
- Whether the ANDA has a design-around that avoids literal infringement or the doctrine of equivalents.
Practical risk model (how companies use these cases):
- If Allergan’s primary asserted patents survive validity challenges, entry risk stays high until the final date of enforceability or until a settlement permits launch.
- If key claims are invalidated early, Aurobindo can accelerate entry if it also satisfies regulatory readiness.
Limitation:
A complete entry-risk assessment requires the actual asserted patents and the case disposition, neither of which is provided.
Is the litigation tied to an Orange Book listing or FDA approval (ANDA/Paragraph IV)?
Yes, by structure:
A suit captioned as an ANDA infringement action under 35 U.S.C. § 271(e)(2) is tied to:
- an ANDA submission,
- FDA approval status,
- and an Orange Book patent list.
What to look for (to answer precisely):
- the RLD name and strength,
- the ANDA applicant’s Paragraph IV certification to each listed patent,
- which patents were asserted in the complaint,
- and whether FDA ultimately approved the ANDA before or after litigation resolution.
Limitation:
No RLD/ANDA identifiers or patent list entries are provided in the prompt, so a precise Orange Book/FDA linkage cannot be stated.
Which product is at issue (drug name, dosage form), and how do the patents map to it?
Patent-to-product mapping depends on:
- active ingredient and dosage form (tablet, capsule, solution),
- specific formulation characteristics (e.g., excipient selection, release profile),
- and method-of-use regimen (if method claims are asserted).
Limitation:
The prompt does not identify the specific drug product, strength, or dosage form at issue, so a patent-to-product mapping cannot be accurately prepared.
How does this case compare with other Allergan v. generic ANDA disputes?
Common patterns in Allergan generic litigation:
- Allergan asserts multiple patents per product, often blending formulation and use patents.
- Generic defendants frequently challenge validity (anticipation/obviousness) and noninfringement based on ANDA manufacturing and proposed labeling.
Comparison dimensions that matter:
- number of asserted patents,
- whether the court resolved claim construction early,
- settlement structure (entry date versus broad dismissal),
- and whether any asserted patents were held invalid.
Limitation:
Without the asserted patent set and disposition for 1:18-cv-00118, meaningful comparison metrics cannot be computed.
Settlement terms and licensing outcomes: what were the commercial deal terms?
Settlement is the usual commercial endpoint:
In ANDA patent disputes, parties often resolve through:
- an agreed launch date tied to patent expiration,
- covenant-not-to-sue language after launch,
- possible royalty structure on product sales, and/or
- dismissal with conditions tied to design-around commitments.
Limitation:
No settlement record or term sheet content is included in the prompt, so a deal-specific analysis cannot be produced.
Key takeaways on litigation strength and future risk
- This case is a Hatch-Waxman infringement dispute between Allergan Sales LLC and Aurobindo Pharma USA Inc., docketed as 1:18-cv-00118, where the legal and commercial outcome is driven by Orange Book patent coverage and remaining enforceability.
- Commercial impact is determined by the asserted patent estate (composition, formulation, and/or method-of-use) and the court’s or settlement’s resolution.
- At-risk generic entry timing hinges on the disposition of primary asserted patents and whether any design-around avoids infringement.
FAQs
1) What is the legal basis for Allergan v. Aurobindo Pharma USA (1:18-cv-00118)?
It is structured as an ANDA patent infringement action under Hatch-Waxman, typically tied to a Paragraph IV certification framework and 35 U.S.C. § 271(e)(2).
2) Which Orange Book patents were asserted in 1:18-cv-00118?
The prompt does not include the asserted patent numbers. A patent-specific answer cannot be produced from the provided information.
3) Does this case result in an injunction against the Aurobindo ANDA?
The prompt does not include the disposition. An injunction outcome cannot be determined from the provided information.
4) When could Aurobindo’s generic launch occur if the case settles?
Launch timing in these matters depends on settlement entry dates tied to patent expiration or earlier court outcomes. The prompt does not include settlement terms.
5) How does claim construction typically affect Hatch-Waxman outcomes?
Claim construction can narrow infringement scope and shift validity or noninfringement arguments, often increasing the odds of settlement or entry depending on how the ANDA product maps to the construed claims.
References (APA)
- United States District Court docket: Allergan Sales LLC v. Aurobindo Pharma USA Inc., 1:18-cv-00118. (Court docket record).
